吸入糖皮质激素与分枝杆菌感染风险
该研究基于加拿大安大略省2001至2013年≥66岁接受治疗的气道阻塞性疾病(哮喘、慢阻肺或哮喘-慢阻肺重叠综合征)成人的实验室与健康行政数据库,开展基于人群的巢式病例对照研究。结果显示,当前使用吸入糖皮质激素(ICS)与NTM-PD风险升高相关(aOR 1.86,95%CI 1.60-2.15),氟替卡松显著(aOR 2.09,95%CI 1.80-2.43),布地奈德不显著(aOR 1.19,95%CI 0.97-1.45);与结核无显著关联(aOR 1.43,95%CI 0.95-2.16)。
要点
- 当前ICS使用与NTM-PD风险升高相关,氟替卡松关联显著而布地奈德不显著。
- NTM-PD风险与1年内累积ICS剂量呈强剂量-反应关系。
- 当前ICS使用与结核风险无显著关联。
核心结论
- ICS使用与NTM-PD风险升高相关,但与TB无显著关联。
研究设计与样本
- 基于人群的巢式病例对照研究,使用加拿大安大略省关联的实验室与健康行政数据库。
- 识别NTM-PD病例2966例、TB病例327例,采用条件 logistic 回归估计比值比。
主要发现
- 当前ICS使用与NTM-PD相关(aOR 1.86,95%CI 1.60-2.15)。
- 氟替卡松与NTM-PD关联显著(aOR 2.09,95%CI 1.80-2.43),布地奈德不显著(aOR 1.19,95%CI 0.97-1.45)。
- 新发NTM-PD与1年内累积ICS剂量呈强剂量-反应关系。
- 当前ICS使用与TB无显著关联(aOR 1.43,95%CI 0.95-2.16)。
关键数值与推荐
- 当前ICS使用 vs 非使用:NTM-PD的aOR 1.86(95%CI 1.60-2.15)。
- 氟替卡松:NTM-PD的aOR 2.09(95%CI 1.80-2.43);布地奈德:aOR 1.19(95%CI 0.97-1.45)。
- 当前ICS使用与TB:aOR 1.43(95%CI 0.95-2.16)。
临床怎么用
- 对老年气道阻塞性疾病患者处方ICS时,应评估NTM-PD风险,尤其考虑氟替卡松及较高累积剂量。
- ICS与TB无显著关联,结核风险评估不应主要依据ICS使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhaled corticosteroid (ICS) use is associated with an increased risk of pneumonia. This study was performed to determine if ICS use is associated with an increased risk of nontuberculous mycobacterial pulmonary disease (NTM-PD) or tuberculosis (TB).We conducted a population-based nested case-control study using linked laboratory and health administrative databases in Ontario, Canada, including adults aged ≥66 years with treated obstructive lung disease (i.e. asthma, chronic obstructive pulmonary disease (COPD) or asthma-COPD overlap syndrome) between 2001 and 2013. We estimated odds ratios comparing ICS use with nonuse among NTM-PD and TB cases and controls using conditional logistic regression.Among 417 494 older adults with treated obstructive lung disease, we identified 2966 cases of NTM-PD and 327 cases of TB. Current ICS use was associated with NTM-PD compared with nonuse (adjusted OR (aOR) 1.86, 95% CI 1.60-2.15) and was statistically significant for fluticasone (aOR 2.09, 95% CI 1.80-2.43), but not for budesonide (aOR 1.19, 95% CI 0.97-1.45). There was a strong dose-response relationship between incident NTM-PD and cumulative ICS dose over 1 year. There was no significant association between current ICS use and TB (aOR 1.43, 95% CI 0.95-2.16).This study suggests that ICS use is associated with an increased risk of NTM-PD, but not TB.
引用
- Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017. PMID: 28931659. doi:10.1183/13993003.00037-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。